Abstract
There was no standard or report for the treatment of rheumatoid arthritis (RA) patients on hemodialysis with Salazosulfapyridine (SASP). We examined the pharmacokinetics of SASP and its metabolites in RA patient on hemodialysis. Hemodialysis was started 2 h after administration of SASP at a dose of 250 or 500 mg. Blood samples were took 8 times during the observation period. The concentration of SASP and its metabolites (SP, Ac-SP) in blood sample were measured. There was no difference for the concentration of SASP before and after hemodialysis. Results showed SASP was nondialyzable, but SP and AC-SP were dialyzable. At a dose of 500 mg, AUC0-∞ of SASP and SP were higher than healthy volunteer. Therapy with SASP for hemodialysis RA should be started at a lower dose for adverse event risk.
This is a preview of subscription content, log in via an institution to check access.
References
Pullar T, Hunter JA, Capell HA (1983) Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 287:1102–1104
Plosker GL, Katherine FC (2005) Sulfasalazine—a review of its use in the management of rheumatoid arthritis. Drugs 65(13):1825–1849
Uchida E, Kai K, Kobayashi S et al (1990) A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ306) in healthy Japanese subjects [in Japanese]. Jpn J Clin Pharmacol Ther 21(2):377–389
Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology (2008) recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 59(6):762–784
Nishioka N, Nobunaga M, Sakuma A (1991) Comparison of sulfasalazine and placebo in a randomized, double-blind controlled dose-finding study in patients with rheumatoid arthritis [in Japanese]. Ryumachi 31(3):327–345
Tanaka E, Taniguchi A, Urano W et al (2002) Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29(12):2492–2499
Akiyama Y, Fujimaki T, Sakurai Y (2003) Pharmacokinetics of salazosulfapyridine in a hemodialysis (in Japanese). Ryumachi 43(3):569–576
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Inami, Y., Yamaji, K., Sato, M. et al. Effects of dialysis on the pharmacokinetics of salazosulfapyridine. Rheumatol Int 33, 535–539 (2013). https://doi.org/10.1007/s00296-011-2179-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2179-1